T
Toshihiro Nukiwa
Researcher at Tohoku University
Publications - 345
Citations - 23599
Toshihiro Nukiwa is an academic researcher from Tohoku University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 66, co-authored 340 publications receiving 21285 citations. Previous affiliations of Toshihiro Nukiwa include University of Tokyo & Nippon Medical School.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Yoichiro Mitsuishi,Keiko Taguchi,Yukie Kawatani,Tatsuhiro Shibata,Toshihiro Nukiwa,Hiroyuki Aburatani,Masayuki Yamamoto,Hozumi Motohashi +7 more
TL;DR: It is shown that Nrf2 redirects glucose and glutamine into anabolic pathways, especially under the sustained activation of PI3K-Akt signaling, which enables NRF2 to promote metabolic activities that support cell proliferation in addition to enhancing cytoprotection.
Journal ArticleDOI
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Arata Azuma,Toshihiro Nukiwa,Eiyasu Tsuboi,Moritaka Suga,Shosaku Abe,Koichiro Nakata,Yoshio Taguchi,Sonoko Nagai,Harumi Itoh,Motoharu Ohi,Atsuhiko Sato,Shoji Kudoh +11 more
TL;DR: Treatment with pirfenidone improved VC and prevented acute exacerbation of IPF during the 9 months of follow-up, and adherence to treatment regimen was similar between pirfenidsone and placebo groups.
Journal ArticleDOI
Pirfenidone in idiopathic pulmonary fibrosis
Hiroyuki Taniguchi,Masahito Ebina,Yasuhiro Kondoh,Takashi Ogura,Arata Azuma,Moritaka Suga,Yoshio Taguchi,Hiroki Takahashi,Koichiro Nakata,Atsuyasu Sato,Masahiro Takeuchi,Ganesh Raghu,Shouji Kudoh,Toshihiro Nukiwa +13 more
TL;DR: Although photosensitivity, a well-established side-effect of pirfenidone, was the major adverse event in this study, it was mild in severity in most of the patients and relatively well tolerated in patients with IPF.
Journal ArticleDOI
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Akira Inoue,Takuji Suzuki,Tatsuro Fukuhara,Makoto Maemondo,Yuichiro Kimura,Naoto Morikawa,Hiroshi Watanabe,Yasuo Saijo,Toshihiro Nukiwa +8 more
TL;DR: Treatment with gefitinib alone for chemotherapy-naïve NSCLC patients with EGFR mutations could achieve a high efficacy with acceptable toxicity, and a subsequent randomized trial comparing gefITinib with standard chemotherapy is warranted.